Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jun 10;40(17):1870-1878.
doi: 10.1200/JCO.21.00714. Epub 2022 Feb 22.

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)

Alan L Ho  1 , Marek Dedecjus  2 , Lori J Wirth  3 , R Michael Tuttle  4 , William B Inabnet 3rd  5   6 , Jan Tennvall  7 , Fernanda Vaisman  8 , Lars Bastholt  9 , Andrew G Gianoukakis  10   11 , Patrice Rodien  12 , Ralf Paschke  13 , Rossella Elisei  14 , David Viola  14 , Karen So  15 , Danielle Carroll  15 , Tina Hovey  16 , Bhavana Thakre  17 , James A Fagin  4 ; ASTRA investigator group
Affiliations
Clinical Trial

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)

Alan L Ho et al. J Clin Oncol. .

Abstract

Purpose: Selumetinib can increase radioactive iodine (RAI) avidity in RAI-refractory tumors. We investigated whether selumetinib plus adjuvant RAI improves complete remission (CR) rates in patients with differentiated thyroid cancer (DTC) at high risk of primary treatment failure versus RAI alone.

Methods: ASTRA (ClinicalTrials.gov identifier: NCT01843062) is an international, phase III, randomized, placebo-controlled, double-blind trial. Patients with DTC at high risk of primary treatment failure (primary tumor > 4 cm; gross extrathyroidal extension outside the thyroid gland [T4 disease]; or N1a/N1b disease with ≥ 1 metastatic lymph node(s) ≥ 1 cm or ≥ 5 lymph nodes [any size]) were randomly assigned 2:1 to selumetinib 75 mg orally twice daily or placebo for approximately 5 weeks (no stratification). On treatment days 29-31, recombinant human thyroid-stimulating hormone (0.9 mg)-stimulated RAI (131I; 100 mCi/3.7 GBq) was administered, followed by 5 days of selumetinib/placebo. The primary end point (CR rate 18 months after RAI) was assessed in the intention-to-treat population.

Results: Four hundred patients were enrolled (August 27, 2013-March 23, 2016) and 233 randomly assigned (selumetinib, n = 155 [67%]; placebo, n = 78 [33%]). No statistically significant difference in CR rate 18 months after RAI was observed (selumetinib n = 62 [40%]; placebo n = 30 [38%]; odds ratio 1.07 [95% CI, 0.61 to 1.87]; P = .8205). Treatment-related grade ≥ 3 adverse events were reported in 25/154 patients (16%) with selumetinib and none with placebo. The most common adverse event with selumetinib was dermatitis acneiform (n = 11 [7%]). No treatment-related deaths were reported.

Conclusion: Postoperative pathologic risk stratification identified patients with DTC at high risk of primary treatment failure, although the addition of selumetinib to adjuvant RAI failed to improve the CR rate for these patients. Future strategies should focus on tumor genotype-tailored drug selection and maintaining drug dosing to optimize RAI efficacy.

PubMed Disclaimer

Conflict of interest statement

Alan L. HoConsulting or Advisory Role: Bristol Myers Squibb, Eisai, Genzyme, Merck, Novartis, Sun Pharma, Eisai, Regeneron, TRM Oncology, Ayala Pharmaceuticals, AstraZeneca, Sanofi, CureVac, Prelude Therapeutics, Kura Oncology, McGivney Global Advisors, Rgenta, AffyImmune Therapeutics, Exelixis, Cellestia, InxmedSpeakers’ Bureau: Medscape, Omniprex America, NovartisResearch Funding: Lilly, Genentech/Roche (Inst), AstraZeneca, Allos Therapeutics, Astellas Pharma, Ayala Pharmaceuticals, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Elevar Therapeutics, Kolltan Pharmaceuticals, Kura Oncology, Merck, Novartis, PfizerTravel, Accommodations, Expenses: Janssen Oncology, Merck, Kura Oncology, Ignyta, Ayala Pharmaceuticals, Klusa Pharma Marek DedecjusHonoraria: Sanofi/Aventis, Bayer, Berlin-ChemieResearch Funding: AstraAzeneca/Merck, Exelixis Lori J. WirthConsulting or Advisory Role: Merck, Loxo, Blueprint Medicines, Eisai, Lilly, Bayer, ExelixisResearching Funding: Checkmate Pharmaceuticals (Inst), Lilly (Inst), Ayala Pharmaceuticals (Inst), Eisai (Inst)Expert Testimony: EisaiOther Relationship: PDS Biotechnology R. Michael TuttleResearch Funding: Elesta (Inst) Fernanda VaismanConsulting or Advisory Role: AstraZeneca/Merck, Ipsen, Lilly, Bayer HealthSpeaker’s Bureau: Bayer, AstraZeneca/Merck, Sanofi, United Medical Lars BastholtResearch Funding: Bristol Myers Squibb (Inst) Andrew G. GianoukakisConsulting or Advisory Role: Eisai, Exelixs Patrice RodienConsulting or Advisory Role: Eisai EuropeResearch Funding: Pfizer (Inst) Ralf PaschkeConsulting or Advisory Role: Bayer, EisaiResearching Funding: Bayer (Inst)Patents, Royalties, Other Intellectual Property: Licensing fee for a diagnostic testRossella EliseiConsulting or Advisory Role: EISAI, Genezyme, Loxo, Ipsen, Bayer, Lilly Karen SoEmployment: AstraZenecaStock and Other Ownership Interests: AstraZeneca Danielle CarrollEmployment: AstraZeneca/MedImmune, Azeria therapeutics (I)Leadership: Azeria therapeutics (I)Stock and Other Ownership Interests: AstraZeneca/MedImmune, Azeria Therapeutics (I)Honoraria: AstraZeneca (I)Consulting or Advisory Role: Azeria therapeutics (I)Research Funding: AstraZeneca (I)Patents, Royalties, Other Intellectual Property: Royalties from Active Motif (I), Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia, Anti-cxc chemokine-2 binding molecules and uses thereof Tina HoveyEmployment: PhastarConsulting or Advisory Role: AstraZenecaResearch Funding: AstraZeneca James A. FaginHonoraria: Eisai EuropeConsulting or Advisory Role: Loxo OncologyPatents, Royalties, Other Intellectual Property: 3. MSK Ref. SK 2014-024-03 Title: Treatment of H-RAS-Driven Tumors. Application Number: 15/305,788. 3. Anti-TSHR Multispecific Antibodies and Uses Thereof, provisional patent.No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
ASTRA trial design. aIncluding papillary thyroid cancer, follicular thyroid cancer, and poorly differentiated thyroid cancer. DTC, differentiated thyroid cancer; RAI, radioactive iodine; rhTSH, recombinant human thyroid-stimulating hormone.
FIG 2.
FIG 2.
Forest plot of complete remission rate at 18 months by subgroup data (ITT analysis set). Population: full analysis set, data cutoff on May 18, 2018. Minimum 10 patients per treatment by factor levels are considered for calculation of OR and CI. Size of circle is proportional to the number of events. The teal band represents the 95% CI for the overall OR. When BRAF/NRAS mutations are summarized together, the status is summarized as known if (1) either BRAF or NRAS mutation is positive or (2) both BRAF and NRAS mutations are not detected. In case one mutation was not detected while the other mutation was unknown, the status is summarized as unknown. ITT, intention-to-treat; OR, odds ratio; RAI, radioactive iodine.
See this image and copyright information in PMC

Comment in

References

    1. Haugen BR, Alexander EK, Bible KC, et al. : 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1-133, 2016 - PMC - PubMed
    1. Castagna MG, Maino F, Cipri C, et al. : Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165:441-446, 2011 - PubMed
    1. Tuttle RM, Tala H, Shah J, et al. : Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: Using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349, 2010 - PMC - PubMed
    1. Vaisman F, Momesso D, Bulzico DA, et al. : Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf) 77:132-138, 2012 - PubMed
    1. Cohen Y, Xing M, Mambo E, et al. : BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627, 2003 - PubMed

Publication types

MeSH terms

Associated data